213 related articles for article (PubMed ID: 17603822)
21. The influence of antidiabetic medications on the development and progression of prostate cancer.
Hitron A; Adams V; Talbert J; Steinke D
Cancer Epidemiol; 2012 Aug; 36(4):e243-50. PubMed ID: 22417708
[TBL] [Abstract][Full Text] [Related]
22. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
Chang Y; Choi NK; Hahn S; Park BJ
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252
[No Abstract] [Full Text] [Related]
23. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
24. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
[TBL] [Abstract][Full Text] [Related]
25. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Hartung DM; Touchette DR; Bultemeier NC; Haxby DG
Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
[TBL] [Abstract][Full Text] [Related]
26. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea.
Chung YW; Han DS; Park KH; Eun CS; Yoo KS; Park CK
Dis Colon Rectum; 2008 May; 51(5):593-7. PubMed ID: 18219529
[TBL] [Abstract][Full Text] [Related]
27. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
28. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
Hsu CC; Wahlqvist ML; Lee MS; Tsai HN
J Alzheimers Dis; 2011; 24(3):485-93. PubMed ID: 21297276
[TBL] [Abstract][Full Text] [Related]
29. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
[TBL] [Abstract][Full Text] [Related]
30. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
[TBL] [Abstract][Full Text] [Related]
31. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes.
Quilliam BJ; Ozbay AB; Sill BE; Kogut SJ
Diabet Med; 2013 Nov; 30(11):1305-13. PubMed ID: 23586474
[TBL] [Abstract][Full Text] [Related]
32. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
Stockl KM; Le L; Zhang S; Harada AS
Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
[TBL] [Abstract][Full Text] [Related]
33. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
McAlister FA; Eurich DT; Majumdar SR; Johnson JA
Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
[TBL] [Abstract][Full Text] [Related]
34. Balancing risk and benefit with oral hypoglycemic drugs.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
[TBL] [Abstract][Full Text] [Related]
35. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.
Gerrits CM; Bhattacharya M; Manthena S; Baran R; Perez A; Kupfer S
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1065-71. PubMed ID: 17674425
[TBL] [Abstract][Full Text] [Related]
36. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
37. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
[TBL] [Abstract][Full Text] [Related]
38. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
Koro CE; Sowell MO; Stender M; Qizilbash N
Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
[TBL] [Abstract][Full Text] [Related]
39. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
40. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Kowall B; Rathmann W; Kostev K
Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]